Stock Events

Stock Events

Sareum 

€0.15
26
+€0+0% Tuesday 07:55

Statistics

Day High
0.15
Day Low
0.13
52W High
0.27
52W Low
0.13
Volume
-
Avg. Volume
-
Mkt Cap
19.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MarExpected
Q1 2023
Q3 2023
Q4 2023
Q3 2024
Q4 2024
Q3 2025
Q4 2025
-3.63
-2.42
-1.21
0
Expected EPS
N/A
Actual EPS
-1.2107986944

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-10.39MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RYH0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.LSE
Mkt Cap237.53B
GSK
GSK.LSE
Mkt Cap85.7B
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb, with a strong portfolio in oncology, cardiovascular, and immunoscience, competes in the development of novel therapies, similar to Sareum's research focus.
Merck
MRK
Mkt Cap298.84B
Merck & Co., known for its innovative cancer treatments and vaccines, competes with Sareum in the oncology and immunotherapy sectors.
Pfizer
PFE
Mkt Cap161.09B
Pfizer, with a broad range of therapeutic areas including oncology, competes with Sareum in the development and commercialization of cancer treatments.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG, specializing in biotechnology products for oncology, immunology, and infectious diseases, competes with Sareum in the cancer research and development space.
Novartis
NVS
Mkt Cap297.32B
Novartis AG, focusing on innovative medicines in areas like oncology and immunology, competes with Sareum in the development of new treatments for cancer and autoimmune diseases.
AMGEN
AMGN
Mkt Cap187.56B
Amgen, with a focus on human therapeutics in areas including oncology/hematology, competes with Sareum in the development of cancer and autoimmune disease treatments.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly and Company, focusing on cancer, endocrinology, and immunology, competes with Sareum in the development of therapies for various diseases, including cancer.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, known for its innovative biotechnology products in oncology and immunology, competes with Sareum in the research and development of treatments for cancer and autoimmune diseases.

About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
Show more...
CEO
Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D.
Employees
5
Country
DE
ISIN
GB00BMC3RJ87
WKN
000A3DWCH

Listings

LSE
GB
SAR.LSE
F
DE
RYH0.F

0 Comments

Share your thoughts

FAQ

What is Sareum stock price today?▼
The current price of RYH0.F is €0.15 EUR — it has increased by +0% in the past 24 hours. Watch Sareum stock price performance more closely on the chart.
What is Sareum stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sareum stocks are traded under the ticker RYH0.F.
Is Sareum stock price growing?▼
RYH0.F stock has risen by +0% compared to the previous week, the month change is a -0.68% fall, over the last year Sareum has showed a -13.1% decrease.
What is Sareum market cap?▼
Today Sareum has the market capitalization of 19.62M
When is the next Sareum earnings date?▼
Sareum is going to release the next earnings report on October 26, 2026.
What were Sareum earnings last quarter?▼
RYH0.F earnings for the last quarter are -0.01 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Sareum revenue for the last year?▼
Sareum revenue for the last year amounts to 0 EUR.
What is Sareum net income for the last year?▼
RYH0.F net income for the last year is -10.39M EUR.
How many employees does Sareum have?▼
As of April 08, 2026, the company has 5 employees.
In which sector is Sareum located?▼
Sareum operates in the Health Care sector.
When did Sareum complete a stock split?▼
The last stock split for Sareum was on March 01, 2022 with a ratio of 1:50.
Where is Sareum headquartered?▼
Sareum is headquartered in Cambridge, DE.